Acute Leukemias of Ambiguous Lineage Have Durable Response to Hypomethylating Agents Plus Venetoclax in Older Patients
Joshua Fein(Dana-Farber Cancer Institute), Justin D. Kaner(NewYork–Presbyterian Hospital), Paul D. Simonson(Cornell University), Michael Kluk(Cornell University), Sanjay S. Patel(NewYork–Presbyterian Hospital), Julia T. Geyer(Cornell University), Madhu M. Ouseph(The Ohio State University), Amy Chadburn(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Michal Bar‐Natan(NewYork–Presbyterian Hospital), Neela Easwar(University of California San Diego), Michael Samuel(NewYork–Presbyterian Hospital), Gail J. Roboz(Cornell University)
Cited by 0
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k